Literature DB >> 8453825

Plasma protein binding of lidocaine and warfarin in insulin-dependent and non-insulin-dependent diabetes mellitus.

S O'Byrne1, M G Barry, W C Collins, P O'Connor, M J Cullen, J Feely.   

Abstract

We examined the plasma protein binding of an acidic drug (warfarin bound to albumin) and a basic drug [lidocaine (lignocaine) bound to alpha 1-acid glycoprotein] in 15 patients with insulin-dependent diabetes mellitus (IDDM) and 15 matched controls. We also examined protein binding of warfarin and lidocaine in 30 patients with non-insulin-dependent diabetes (NIDDM) and 25 controls. Compared with control, the binding of both warfarin (98.81 +/- 0.02 vs 98.57 +/- 0.03%, mean +/- SEM) and of lidocaine (69 +/- 2 vs 58 +/- 2%) was significantly reduced in IDDM. This group had lower concentrations of both albumin and alpha 1-acid glycoprotein (AAG), achieving statistical significance vs control for albumin only. In the patients with NIDDM, who had a similar level of glycosylated haemoglobin, while there was no significant difference in the binding of lidocaine there was a significant increase in warfarin binding compared with the control population (99.01 +/- 0.03 vs 98.82 +/- 0.04%). This study suggests that binding of both acidic and basic drugs is altered in both IDDM and NIDDM.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8453825     DOI: 10.2165/00003088-199324020-00007

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  9 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part I).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 2.  Drug binding to human alpha-1-acid glycoprotein in health and disease.

Authors:  J M Kremer; J Wilting; L H Janssen
Journal:  Pharmacol Rev       Date:  1988-03       Impact factor: 25.468

3.  Isolation of inhibitors of ligand: albumin-binding from uremic body fluids and normal urine.

Authors:  P F Gulyassy; A T Bottini; E A Jarrard; L A Stanfel
Journal:  Kidney Int Suppl       Date:  1983-12       Impact factor: 10.545

Review 4.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

Review 5.  The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans.

Authors:  P R Gwilt; R R Nahhas; W G Tracewell
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

6.  Glucosylated albumin and its influence on salicylate binding.

Authors:  K A Mereish; H Rosenberg; J Cobby
Journal:  J Pharm Sci       Date:  1982-02       Impact factor: 3.534

7.  Plasma protein carbamylation and decreased acidic drug protein binding in uremia.

Authors:  S Erill; R Calvo; R Carlos
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

8.  Abnormal serum protein binding of acidic drugs in diabetes mellitus.

Authors:  F Ruiz-Cabello; S Erill
Journal:  Clin Pharmacol Ther       Date:  1984-11       Impact factor: 6.875

9.  Serum protein binding of phenytoin and valproic acid in insulin-dependent diabetes mellitus.

Authors:  G Gatti; F Crema; G Attardo-Parrinello; P Fratino; F Aguzzi; E Perucca
Journal:  Ther Drug Monit       Date:  1987-12       Impact factor: 3.681

  9 in total
  3 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 2.  Measurement and analysis of unbound drug concentrations.

Authors:  J D Wright; F D Boudinot; M R Ujhelyi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

3.  Focused ultrasound enhances the anesthetic effects of topical lidocaine in rats.

Authors:  Hyun-Chul Kim; Wonhye Lee; Mark Böhlke; Kyungho Yoon; Seung-Schik Yoo
Journal:  BMC Anesthesiol       Date:  2021-05-21       Impact factor: 2.217

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.